Literature DB >> 8707861

C-myc expression affects proliferation but not terminal differentiation or survival of explanted erythroid progenitor cells.

M C Bondurant1, T Yamashita, K Muta, S B Krantz, M J Koury.   

Abstract

The expression of c-myc was analyzed in murine and human erythroblasts throughout their differentiation in vitro into reticulocytes. The murine cells were splenic erythroblasts from animals infected with the anemia strain of Friend virus (FVA cells). In FVA cells cultured without EPO, the c-myc mRNA and protein levels decrease sharply within 3 to 4 h, showing that continual EPO stimulation is required to maintain c-myc expression. When cultured with EPO, the c-myc mRNA level of FVA cells is raised within 30 min of exposure. The c-myc mRNA and protein reach maxima at 1 to 3 h, then decline slowly to very low levels by 18 h. In contrast, c-fos and c-jun mRNA levels are not regulated by EPO in FVA cells. The human cells analyzed were colony-forming units-erythroid, CFU-E, derived in vitro by the culture of peripheral blood burst-forming units-erythroid (BFU-E). When grown in EPO and insulin-like growth factor 1 (IGF-1) these cells differentiate into reticulocytes over 6 days rather than the 2 days required for murine cells, but the c-myc mRNA kinetics and response to EPO parallel those of mouse cells at similar stages of differentiation. Both IGF-1 and c-kit ligand (SCF) cause an additive increase in c-myc mRNA in human CFU-E in conjunction with EPO. These additive effects suggest that EPO, IGF-1, and SCF affect c-myc mRNA accumulation by distinct mechanisms. Addition of an antisense oligonucleotide to c-myc in cultures of human CFU-E specifically inhibited cell proliferation but did not affect erythroid cell differentiation or apoptosis. When human cells were grown in high SCF concentrations, an environment which enhances proliferation and retards differentiation, antisense oligonucleotide to c-myc strongly inhibited proliferation, but such inhibition did not induce differentiation. This latter result indicates that differentiation requires signals other than depression of c-Myc and resultant depression of proliferation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8707861     DOI: 10.1002/(SICI)1097-4652(199608)168:2<255::AID-JCP4>3.0.CO;2-O

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  5 in total

1.  Both the polycythemia- and anemia-inducing strains of Friend spleen focus-forming virus induce constitutive activation of the Raf-1/mitogen-activated protein kinase signal transduction pathway.

Authors:  K W Muszynski; T Ohashi; C Hanson; S K Ruscetti
Journal:  J Virol       Date:  1998-02       Impact factor: 5.103

2.  Extensive ex vivo expansion of functional human erythroid precursors established from umbilical cord blood cells by defined factors.

Authors:  Xiaosong Huang; Siddharth Shah; Jing Wang; Zhaohui Ye; Sarah N Dowey; Kit Man Tsang; Laurel G Mendelsohn; Gregory J Kato; Thomas S Kickler; Linzhao Cheng
Journal:  Mol Ther       Date:  2013-09-03       Impact factor: 11.454

3.  Differential gene expression during terminal erythroid differentiation.

Authors:  S Koury; S Yarlagadda; K Moskalik-Liermo; N Popli; N Kim; C Apolito; A Peterson; X Zhang; P Zu; J Tamburlin; D Bofinger
Journal:  Genomics       Date:  2007-08-31       Impact factor: 5.736

4.  Erythropoietin drives breast cancer progression by activation of its receptor EPOR.

Authors:  Ka Kui Chan; Kyle B Matchett; Jonathan A Coulter; Hiu-Fung Yuen; Cian M McCrudden; Shu-Dong Zhang; Gareth W Irwin; Matthew A Davidson; Thomas Rülicke; Sophie Schober; Ludger Hengst; Heidelinde Jaekel; Angela Platt-Higgins; Philip S Rudland; Ken I Mills; Perry Maxwell; Mohamed El-Tanani; Terence R Lappin
Journal:  Oncotarget       Date:  2017-06-13

5.  DKC1 is a transcriptional target of GATA1 and drives upregulation of telomerase activity in normal human erythroblasts.

Authors:  Laura A Richards; Ashu Kumari; Kathy Knezevic; Julie Ai Thoms; Georg von Jonquieres; Christine E Napier; Zara Ali; Rosemary O'Brien; Jonathon Marks-Bluth; Michelle F Maritz; Hilda A Pickett; Jonathan Morris; John E Pimanda; Karen L MacKenzie
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.